|
 
- 积分
- 590
- 威望
- 590
- 包包
- 1609
|
本帖最后由 宗介 于 2020-7-17 21:12 编辑 r# P" {! G s9 c9 S
4 v" U! A8 Q1 I! p: X$ i
* f& R6 k6 X, d5 @ E$ X6 w, F/ u. F+ o6 I" u5 m: f
This book systematically reviews the most important findings on cancer immune checkpoints, sharing essential insights into this rapidly evolving yet largely unexplored research topic. The past decade has seen major advances in cancer immune checkpoint therapy, which has demonstrated impressive clinical benefits. The family of checkpoints for mediating cancer immune evasion now includes CTLA-4, PD-1/PD-L1, CD27/CD70, FGL-1/LAG-3, Siglec-15, VISTA (PD-1L)/VSIG3, CD47/SIRPA, APOE/LILRB4, TIGIT, and many others. Despite these strides, most patients do not show lasting remission, and some cancers have been completely resistant to the therapy. The potentially lethal adverse effects of checkpoint blockade represent another major challenge, the mechanisms of which remain poorly understood. Compared to the cancer signaling pathways, such as p53 and Ras, mechanistic studies on immune checkpoint pathways are still in their infancy. To improve the responses to checkpoint blockade therapy and limit the adverse effects, it is essential to understand the molecular regulation of checkpoint molecules in both malignant and healthy cells/tissues. This book begins with an introduction to immune checkpoint therapy and its challenges, and subsequently describes the regulation of checkpoints at different levels. In closing, it discusses recent therapeutic developments based on mechanistic findings, and outlines goals for future translational studies. The book offers a valuable resource for researchers in the cancer immunotherapy field, helping to form a roadmap for checkpoint regulation and develop safer and more effective immunotherapies.( m8 ]# X4 B! m3 m3 F
% \. |6 O) w3 X; p
% ~5 N) [, c# s" K( t |
附件: 你需要登录才可以下载或查看附件。没有帐号？注册
|
发表于 2020-7-17 21:11
